AIMMS suite: a web server dedicated for prediction of drug resistance on protein mutation

Drug resistance is one of the most intractable issues for successful treatment in current clinical practice. Although many mutations contributing to drug resistance have been identified, the relationship between the mutations and the related pharmacological profile of drug candidates has yet to be fully elucidated, which is valuable both for the molecular dissection of drug resistance mechanisms and for suggestion of promising treatment strategies to counter resistant. Hence, effective prediction approach for estimating the sensitivity of mutations to agents is a new opportunity that counters drug resistance and creates a high interest in pharmaceutical research. However, this task is always hampered by limited known resistance training samples and accurately estimation of binding affinity. Upon this challenge, we successfully developed Auto In Silico Macromolecular Mutation Scanning (AIMMS), a web server for computer-aided de novo drug resistance prediction for any ligand-protein systems. AIMMS can qualitatively estimate the free energy consequences of any mutations through a fast mutagenesis scanning calculation based on a single molecular dynamics trajectory, which is differentiated with other web services by a statistical learning system. AIMMS suite is available at http://chemyang.ccnu.edu.cn/ccb/server/AIMMS/.

[1]  David S. Goodsell,et al.  The RCSB protein data bank: integrative view of protein, gene and 3D structural information , 2016, Nucleic Acids Res..

[2]  Fengyong Liu,et al.  Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[3]  Demin Liu,et al.  Nanoscale Metal–Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells , 2014, Journal of the American Chemical Society.

[4]  Phelim Bradley,et al.  Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis , 2015, Nature Communications.

[5]  Anna Maria Almerico,et al.  Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis , 2008, J. Comput. Aided Mol. Des..

[6]  Eyke Hüllermeier,et al.  Multilabel classification for exploiting cross-resistance information in HIV-1 drug resistance prediction , 2013, Bioinform..

[7]  R. Shafer,et al.  2017 Update of the Drug Resistance Mutations in HIV-1. , 2016, Topics in antiviral medicine.

[8]  Phelim Bradley,et al.  Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study , 2015, The Lancet. Infectious diseases.

[9]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[10]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Sarah A Heerboth,et al.  Drug Resistance in Cancer: An Overview , 2014, Cancers.

[12]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[13]  Ge-Fei Hao,et al.  Understanding the mechanism of drug resistance due to a codon deletion in protoporphyrinogen oxidase through computational modeling. , 2009, The journal of physical chemistry. B.

[14]  S. Laufer,et al.  Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[15]  Kenneth M Merz,et al.  A Fast QM/MM (Quantum Mechanical/Molecular Mechanical) Approach to Calculate Nuclear Magnetic Resonance Chemical Shifts for Macromolecules. , 2006, Journal of chemical theory and computation.

[16]  M. Pierotti,et al.  Targeted therapy in GIST: in silico modeling for prediction of resistance , 2011, Nature Reviews Clinical Oncology.

[17]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[18]  Ge-Fei Hao,et al.  Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex. , 2012, Journal of the American Chemical Society.

[19]  Chang-Guo Zhan,et al.  Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. , 2008, Journal of the American Chemical Society.

[20]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.

[21]  M. Miranda,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3. , 1991, Journal of medicinal chemistry.

[22]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[23]  M. Deininger,et al.  Resistance to imatinib: mutations and beyond. , 2010, Seminars in hematology.

[24]  M L Lamb,et al.  Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.

[25]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[26]  K. Merz,et al.  Large-scale validation of a quantum mechanics based scoring function: predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes. , 2005, Journal of medicinal chemistry.

[27]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[28]  Jan Albert,et al.  Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. Duyster,et al.  Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[30]  D. J. Price,et al.  A modified TIP3P water potential for simulation with Ewald summation. , 2004, The Journal of chemical physics.

[31]  Daniel J. Wilson,et al.  Prediction of Staphylococcus aureus Antimicrobial Resistance by Whole-Genome Sequencing , 2014, Journal of Clinical Microbiology.

[32]  Robert M. Hanson,et al.  Jmol SMILES and Jmol SMARTS: specifications and applications , 2016, Journal of Cheminformatics.

[33]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[34]  D. Fan,et al.  Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. , 2014, Cancer letters.

[35]  Mihai Pop,et al.  ARDB—Antibiotic Resistance Genes Database , 2008, Nucleic Acids Res..

[36]  Elena R. Lozovsky,et al.  Biophysical principles predict fitness landscapes of drug resistance , 2016, Proceedings of the National Academy of Sciences.

[37]  Hong Yan,et al.  Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics , 2016, Proteome Science.

[38]  Araz Jakalian,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method , 2000 .

[39]  Christopher I. Bayly,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation , 2002, J. Comput. Chem..

[40]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[41]  Ge-Fei Hao,et al.  Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem. , 2012, Drug discovery today.

[42]  Ryan H. Lilien,et al.  Efficient a Priori Identification of Drug Resistant Mutations Using Dead-End Elimination and MM-PBSA , 2012, J. Chem. Inf. Model..

[43]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[44]  William A. McLaughlin,et al.  Evaluating the potency of HIV‐1 protease drugs to combat resistance , 2008, Proteins.

[45]  Chun Wu,et al.  Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone , 2016, J. Chem. Inf. Model..

[46]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[47]  Ge-Fei Hao,et al.  Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors. , 2010, The journal of physical chemistry. B.

[48]  Ram Samudrala,et al.  PIRSpred: a web server for reliable HIV-1 protein-inhibitor resistance/susceptibility prediction. , 2005, Trends in microbiology.

[49]  A. Ullrich,et al.  Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.

[50]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[51]  Hong Huang Lin,et al.  Computer prediction of drug resistance mutations in proteins. , 2005, Drug discovery today.